BioCryst to Report Fourth Quarter 2021 Financial Results on February 23

Rhea-AI Summary

BioCryst Pharmaceuticals, Inc. (BCRX) plans to release its fourth quarter and full year 2021 financial results on February 23, 2022. A conference call and webcast will follow at 8:30 a.m. ET to discuss the results and provide a corporate update. Investors can access the call via telephone or online, with a replay available afterward. BioCryst specializes in discovering novel oral medicines for rare diseases, with products like ORLADEYO and ongoing development programs targeting complement-mediated diseases and viral infections.

Positive

• Scheduled conference call for Q4 and full year 2021 results may indicate transparency and engagement with investors.
• Ongoing development programs highlight BioCryst's commitment to addressing unmet medical needs in rare diseases.

Negative

• None.

RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2021 financial results Wednesday, February 23, 2022.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 6365545. A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference ID # 6365545.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO^® (berotralstat) is approved in the United States, the European Union, Japan, the United Kingdom and the United Arab Emirates. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB^® (peramivir injection) has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Contact:
Investors
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com

FAQ

When will BioCryst Pharmaceuticals report Q4 2021 results?

BioCryst Pharmaceuticals will report Q4 2021 results on February 23, 2022.

What time is the BioCryst Pharmaceuticals conference call?

The conference call is scheduled for 8:30 a.m. ET on February 23, 2022.

How can I access the BioCryst Pharmaceuticals earnings call?

The earnings call can be accessed by dialing 877-303-8027 for domestic callers or 760-536-5165 for international callers.

What products does BioCryst Pharmaceuticals focus on?

BioCryst specializes in oral small-molecule medicines for rare diseases, including ORLADEYO and RAPIVAB, among others.